Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775175 | 0.77 | CCR3 (0.63) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6774728 | 0.77 | CCR3 (0.63) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1502363 | 0.76 | POLB (0.55) | SLC6A4POLBGBA1 | |
| SCHEMBL6773715 | 0.74 | CCR3 (0.80) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6773816 | 0.74 | CCR3 (0.80) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4164002 | 0.73 | DRD2 (0.42) | — | |
| SCHEMBL4164000 | 0.73 | DRD2 (0.42) | — | |
| SCHEMBL6860109 | 0.73 | DRD2 (0.42) | — | |
| SCHEMBL6773777 | 0.73 | CCR3 (0.57) | CCR3SLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL6779131 | 0.73 | CCR3 (0.55) | CCR3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| EP-2256114-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | CCR3 1978/4885SLC6A2 398/4885SLC6A4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.